Bridging the Gap Between Participants and Clinical Trials

A Phase 3 Study Evaluating the Safety and Effectiveness of Switching to a Once-Weekly Islatravir/Lenacapavir Regimen Compared to Continuing Standard Daily HIV Therapy in Virologically Suppressed Adults – ISLEND 2

CONDITION

Inflammatory and Immune System

GENDER

All

AGE GROUP

From 18

and above

STATUS

Active, not recruiting

This study is testing whether people with HIV whose virus is already well controlled can safely switch from their current daily HIV medicines to a new once-a-week pill (islatravir/lenacapavir).

CONTACT DETAILS

Clinical Trial Site: Taylor Square Private Clinic
Phone Number: 0293316151 Email: trials@tspc.com.au Location: 393 Bourke Street, Surry Hills NSW, Australia

Studies Contact Form

Name*
First Last
Email*
Phone Number
Message*
CAPTCHA
- Send me updates about clinical trials
This field is hidden when viewing the form
All
- All

Approved By: Bellberry

Clinical Trial Registry Link: Click Here